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Cognitive behavioural therapy for insomnia
in patients with rheumatoid arthritis:
protocol for the randomised, single-
blinded, parallel-group Sleep-RA trial
K. M. Latocha1*, K. B. Løppenthin2, M. Østergaard1,3, P. J. Jennum3,4, R. Christensen5,6, M. Hetland1,3, H. Røgind7,
T. Lundbak7, J. Midtgaard8,9 and B. A. Esbensen1,3
Abstract
Background: More than half of patients with rheumatoid arthritis complain of insomnia, which is predominantly
treated with hypnotic drugs. However, cognitive behavioural therapy for insomnia is recommended as the first-line
treatment in international guidelines on sleep. Patients with rheumatoid arthritis suffer from debilitating symptoms,
such as fatigue and pain, which can also be linked to sleep disturbance. It remains to be determined whether
cognitive behavioural therapy for insomnia can be effective in patients with rheumatoid arthritis. The aim of the
Sleep-RA trial is to investigate the efficacy of cognitive behavioural therapy for insomnia on sleep and disease-
related symptoms in patients with rheumatoid arthritis. The primary objective is to compare the effect of cognitive
behavioural therapy for insomnia relative to usual care on changes in sleep efficiency from baseline to week 7 in
patients with rheumatoid arthritis. The key secondary objectives are to compare the effect of cognitive behavioural
therapy for insomnia relative to usual care on changes in sleep onset latency, wake after sleep onset, total sleep
time, insomnia, sleep quality, fatigue, impact of rheumatoid arthritis and depressive symptoms from baseline to
week 26 in patients with rheumatoid arthritis.
Methods: The Sleep-RA trial is a randomised controlled trial with a two-group parallel design. Sixty patients with
rheumatoid arthritis, insomnia and low-to-moderate disease activity will be allocated 1:1 to treatment with
cognitive behavioural therapy for insomnia or usual care. Patients in the intervention group will receive nurse-led,
group-based cognitive behavioural therapy for insomnia once a week for 6 weeks. Outcome assessments will be
carried out at baseline, after treatment (week 7) and at follow-up (week 26).
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Discussion: Data on treatment of insomnia in patients with rheumatoid arthritis are sparse. The Sleep-RA trial is the
first randomised controlled trial to investigate the efficacy of cognitive behavioural therapy for insomnia in patients
with rheumatoid arthritis. Because symptoms of rheumatoid arthritis and insomnia have many similarities, we also
find it relevant to investigate the secondary effects of cognitive behavioural therapy for insomnia on fatigue, impact
of rheumatoid arthritis, depressive symptoms, pain, functional status, health-related quality of life and disease
activity.
If we find cognitive behavioural therapy for insomnia to be effective in patients with rheumatoid arthritis this will
add weight to the argument that evidence-based non-pharmacological treatment for insomnia in rheumatological
outpatient clinics is eligible in accordance with the existing international guidelines on sleep.
Trial registration: ClinicalTrials.gov: NCT03766100. Registered on 30 November 2018.
Keywords: Inflammatory arthritis, Insomnia, Sleep disturbance, Cognitive behavioural therapy for insomnia, Non-
pharmacological treatment, Polysomnography, Actigraphy, Fatigue, Impact of rheumatoid arthritis, Health-related
quality of life
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Introduction
Background and rationale {6a}
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune
inflammatory disease with a prevalence worldwide of
0.4–1.3%. Women are affected three times more
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frequently than men, and onset is most often at 50–60
years of age [1, 2]. Symptoms include joint swelling, pain
and stiffness, and often significant disability. Disease
activity is most commonly monitored with Disease
Activity Score-28 C-reactive protein (DAS28-CRP) based
on the number of swollen joints, the number of tender
joints, serum CRP and patient global assessment [3, 4].
Improvements in early diagnosis and medical treatment
with anti-rheumatic drugs have led to a reduced incidence
of swollen and tender joints, pain and joint destruction
[5]. Nevertheless, patients still report a wide range of
symptoms with a high prevalence; among the most fre-
quently reported are sleep disturbances, fatigue, depressive
symptoms, pain, reduced functional status and health-
related quality of life (HRQoL) [6–8]. In evaluating their
medical treatment with antirheumatic drugs, patients indi-
cate that sleep is one of the most important parameters.
This highlights the major impact that sleep has on phys-
ical and mental well-being [9, 10].
Sleep disturbances are common in patients with RA, with
a prevalence of 60–80% compared to 10–30% in the
general population [11–13]. Furthermore, sleep quality can
be associated with disease activity; for example, patients
with moderate and high disease activity reported fewer
hours asleep than patients with low disease activity or those
in remission [14–17]. Sleep disturbances in patients with
RA are characterised by significantly worse sleep efficiency
(SE), sleep quality, sleep latency, number of awakenings,
and time awake after sleep onset than healthy control
groups [14, 18–20].
Insomnia
According to the International Classification of Sleep
Disorders third edition (ICSD-3) and the Diagnostic and
Statistical Manual of Mental Disorders the diagnostic
criteria for insomnia are: sleep initiation or maintenance
problems; inadequate opportunity and circumstances to
sleep; and daytime consequences [21, 22]. The ICSD-3
duration criterion for chronic insomnia disorder is 3
months and a frequency criterion of at least three times
per week [21]. Like RA, insomnia is associated with fa-
tigue, depressive symptoms, pain, functional status and
cardiovascular diseases [23–25].
The association between disease activity and sleep is
acknowledged in patients with inflammatory arthritis,
but the exact underlying mechanisms of insomnia in
general have not been identified. Insomnia is often
considered to be linked to hyperarousal, which decreases
the likelihood of sleep; however, the heterogeneity in
cause, symptoms, course, comorbidities and
consequences complicates the establishment of a
universal aetiological or pathophysiological model of
insomnia [26, 27]. According to existing evidence on the
pathophysiology of insomnia, insomnia is most likely to
develop in people who have increased genetic risk and
who experience abnormalities in neurobiological
processes—vulnerabilities that may lead to hyperarousal
and to psychological and behavioural processes that
increase the risk for developing insomnia [27–29].
According to the conceptual “3P model” of insomnia by
Spielman et al., three elements contribute to the
development and maintenance of chronic insomnia:
predisposing factors, precipitating events, and perpetuating
mechanisms [30]. The predisposing factors include the fact
that some individuals may have an increased risk of
insomnia by having certain genetic predisposing factors of
personal vulnerability that might contribute to a highly
sensitive or malfunctioning biological sleep system or a
hyperactive arousal system that interferes with sleep [31].
The time of diagnosis can be a precipitating event as being
diagnosed with a chronic disease like RA can cause a
cognitive and emotional reaction. These reactions can
manifest as worry or depressed mood, which may also
exploit the vulnerability of a highly reactive sleep system
[32]. For patients already diagnosed with RA, several
conditions related to their arthritis can represent
precipitating events that contribute to the development of
insomnia—for example, fatigue, pain, reduced functional
status, flares and disease activity [33–35].
When insomnia becomes chronic, sleep is characterised
by inappropriate habits and dysfunctional thoughts related
to sleep, i.e. the perpetuating mechanisms. Insomnia is
often linked to maladaptive strategies, such as avoidance
behaviour during waking hours. Avoidance behaviour may
include cancelling planned activities either because of
feeling too tired or due to fear that the activities will
interfere with sleep. Also, increased sleep effort is
common, e.g. spending excessive time in bed and
developing rigid sleep-related rituals. In response to in-
somnia, some people also develop sleep-interfering cogni-
tions, such as overestimating and worrying about the
negative consequences of insomnia and approaching bed
time with fear of failure [30, 36].
Treatment of insomnia
The predominant treatment for insomnia is hypnotic
drugs [37]. However, hypnotic drugs cause many side
effects, including increased risk of falls resulting in
fracture, cognitive impairment, impaired motor
coordination, sedation, confusion, motor vehicle
accidents, tolerance and dependence [38, 39], and are
associated with increased mortality and risk of dementia
[40–42]. In the search for non-pharmacological treat-
ments for insomnia without severe side effects and with
longer-lasting effects, clinical trials have tested the ef-
fects of exercise, thought control, imagery training, acu-
puncture, paradoxical intention, mindfulness and
cognitive behavioural therapy for insomnia (CBT-i) [43–
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45]. Currently, non-pharmacological treatment for in-
somnia in patients with RA has focused only on physical
activity and exercise training [46, 47].
However, hypnotic drugs do not address the
precipitating events or perpetuating mechanisms that
maintain chronic insomnia, and precipitating events or
perpetuating mechanisms are not the primary focus or
purpose of physical activity or exercise training.
Furthermore, some patients can be disabled to a degree
that inhibits them engaging in physical activity or
exercise training. CBT-i is recommended as the first-line
treatment for insomnia as it has demonstrated more ef-
fects than hypnotic drugs and has demonstrated a long-
term effect [48–51]. In clinical settings, CBT-i is most
often carried out by psychologists; however, treatment
with CBT-i in groups led by nurses has been tested and
the results showed significant positive effects [52, 53].
According to Morin and his model “The vicious circle
of persistent insomnia”, the effect of CBT-i is caused by
its ability to modify thought patterns and behaviours
that reinforce poor sleep [54]. Thus, it is highly relevant
to investigate the efficacy of CBT-i in patients with RA
and, to our knowledge, this is the first clinical trial to in-
vestigate CBT-i in this population.
Objectives {7}
Our primary objective is to compare the effect of CBT-i
relative to usual care on changes in SE from baseline to
week 7 in patients with RA.
Our key secondary objectives are to compare the effect
of CBT-i relative to usual care on changes in sleep onset
latency (SOL), wake after sleep onset (WASO), total
sleep time (TST), insomnia, sleep quality, fatigue, impact
of RA and depressive symptoms from baseline to week
26 in patients with RA.
Other secondary objectives are to compare the effect
of CBT-i relative to usual care on changes in SE, SOL,
WASO, TST, insomnia, sleep quality, fatigue, impact of
RA, depressive symptoms, disease activity, tender joints,
swollen joints, acute-phase reactant value, patient global
assessment, physician global assessment, pain, functional
status and HRQoL from baseline to weeks 7 and 26 in
patients with RA.
Trial design {8}
The Sleep-RA trial will be carried out as a rando-
mised controlled trial with a two-group parallel
design. Participants (n = 60) will be allocated 1:1 to
either CBT-i as treatment (intervention group) or to
usual care (control group). Outcome assessments will
be conducted three times for each participant: at
baseline, after treatment (week 7) and at follow-up
(week 26), as presented in Fig. 1.
Methods: participants, interventions and
outcomes
Study setting {9}
We will recruit patients from hospital rheumatology
outpatient clinics in The Capital Region of Denmark and
Region Zealand are the official names of the two regions
we recruite participants from.
Eligibility criteria {10}
Inclusion criteria
Participants will be included if they: are diagnosed with RA
according to the American College of Rheumatology/
European League Against Rheumatism 2010 criteria [55];
have low to moderate disease activity, defined as DAS28-
CRP ≤5.1 [4] and are 18 years of age or older; have both in-
somnia, defined as Insomnia Severity Index ≥11 [56] and
chronic insomnia, according to the ICSD-3 duration criter-
ion [29, 57]; have unchanged treatment with anti-rheumatic
drugs for the preceding 3 months and no indication for
changes of treatment with antirheumatic drugs during the
intervention; and are able to understand and read Danish.
Exclusion criteria
Patients will be excluded if they: have had glucocorticoid
administered by intramuscular, intra-articular or intraven-
ous methods within the preceding 4 weeks; are on a con-
tinuous current daily intake of oral glucocorticoids >5mg/
day; have had a change in oral glucocorticoid dose within
the preceding 3 months; have had prior or current profes-
sional non-pharmacological treatment for insomnia; work
at night during the intervention, are pregnant or nursing a
baby; have a current alcohol or drug-use disorder, accord-
ing to their medical journal; have patient-related circum-
stances (physical or mental) that impede their ability to
give informed consent and adhere to the programme.
Who will take informed consent? {26a}
The corresponding author (KML) is the project manager
of Sleep-RA and will obtain informed consent from
participants.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
On the consent form, participants are asked to sign if they
agree to have been given written and oral information on
the purpose, method, advantages and disadvantages of
saying yes to participate in the trial, and if they agree to
participate voluntary. On the consent form, participants
are informed that they can withdraw the consent without
losing any rights to treatment, either current or future.
They are also asked if they agree to the use of their data
should they choose to withdraw from the trial.
This trial does not involve collecting biological
specimens for storage.
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Interventions
Both groups will continually receive relevant treatment
for their RA.
Explanation for the choice of comparators {6b}
There are no standards on when and how to identify
sleep disturbances in rheumatology outpatient
consultations. Participants in the control group will
receive usual care on sleep, which in the rheumatology
outpatient clinics in The Capital Region of Denmark and
in Region Zealand is sporadic and random and
conducted via casual conversations based on the general
knowledge of rheumatologists or nurses. Participants in
the control group will be encouraged by KML to
maintain their usual everyday lives and sleep patterns
until follow-up assessment is conducted.
Intervention description {11a}
In the Sleep-RA trial, CBT-i is a 6-week intervention
with participant attendance of 2 h per week. The inter-
vention will be conducted in groups of two to six partici-
pants per group. All sessions will be conducted by KML,
who is a trained nurse in CBT-i.
Fig. 1 Study flowchart
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The manual for the CBT-i intervention in Sleep-RA
has been developed by KML, KBL and BAE in collabor-
ation with a clinical psychologist trained in CBT-i and
patient research partners, in accordance with the “Tem-
plate for Intervention Description and Replication”
checklist and guide [58]. The manual is guided by theory
on CBT-i, available evidence and previous CBT-i man-
uals [54, 59–66]. The CBT-i intervention consists of
sleep education, stimulus control, sleep restriction, cog-
nitive therapy and relaxation, as presented in Table 1.
The CBT-i intervention includes presentations by KML,
exchanges of experiences, assignments, relaxation exer-
cises and individual and shared discussions and reflec-
tions on how to use the knowledge gained during the
intervention and changed habits related to sleep in daily
life.
Criteria for discontinuing or modifying allocated
interventions {11b}
If a participant in the intervention group is not able to
participate in one CBT-i session due to unforeseen cir-
cumstances, an individual session is planned as soon as
possible.
Strategies to improve adherence to interventions {11c}
Adherence enhancement strategies are in use
throughout the trial period, e.g. patients are informed of
the importance of adhering regardless of allocation, and
participants are offered reimbursements for travel [67].
Relevant concomitant care permitted or prohibited during
the trial {11d}
Participants are prohibited from participating in any
professional non-pharmacological treatment for insom-
nia other than Sleep-RA during the trial period.
Provisions for post-trial care {30}
Participants allocated to the control group will be
offered a nurse consultation in the rheumatology
outpatient clinic with a focus on sleep when follow-up
assessment is conducted.
Outcomes {12}
Primary outcome
The primary outcome is SE at week 7 assessed by
polysomnography (PSG) [68]. SE percentage = (TST/
total time in bed (lights out to lights on)) × 100. In
healthy persons, SE is 85–90%.
PSG is a comprehensive study of the biophysiological
changes that occur in the human body during sleep. In
Sleep-RA, 17 electrodes will be attached to each partici-
pant, recording data from electroencephalogram, eye
movements electro-oculogram, electromyogram muscle
activity or skeletal muscle activation, heart rhythm,
respiratory airflow, respiratory effort and peripheral
pulse oximetry [69]. All PSG studies will be conducted
in the participants’ own homes. Data from PSG will be
analysed in epochs of 30 s and managed at the Danish
Center for Sleep Medicine (DCSM), Rigshospitalet,
Glostrup.
Key secondary outcomes
We will examine the effect of improved sleep on key
sleep outcomes and key RA outcomes at follow-up at
week 26 if CBT-i has a significant positive effect on the
primary outcome of SE after treatment at week 7, as pre-
sented in Fig. 2.
Key sleep outcomes SOL will be assessed with PSG.
SOL is the amount of time it takes to go from being
fully awake to being asleep [70].
WASO will be assessed with PSG. WASO is the
cumulative time awake between sleep onset and the final
morning awakening [70].
TST will be assessed with PSG. TST is the cumulative
time asleep between sleep onset and the final morning
awakening [70].
Insomnia will be assessed with the Insomnia Severity
Index questionnaire. This is a seven-item questionnaire
designed to evaluate insomnia severity based on difficul-
ties falling asleep, night-time awakenings, early morning
awakenings, impairment of daytime functioning due to
sleep problems, noticeability of impairments, distress or
worry caused by sleep difficulties and dissatisfaction with
sleep over the past 2 weeks. Each item is rated using a
five-point Likert scale ranging from 0 (not at all) to 4
(very much), for a total score ranging from 0 (no insom-
nia) to 28 (clinical insomnia) [71]. A cut-off of 11 has
been validated in a clinical sample of people with insom-
nia and demonstrated a sensitivity of 97.2% and a speci-
ficity of 100% [56].
Sleep quality will be assessed with the Pittsburgh Sleep
Quality Index (PSQI) questionnaire. The PSQI measures
self-reported sleep over the past 4 weeks [72]. It includes
nine items/18 questions with seven categories, including
subjective sleep quality, sleep latency, sleep duration, ha-
bitual SE, sleep disturbances, use of sleep medications
and daytime dysfunction. A global sum score for the
PSQI >5 indicates poor sleep. The Cronbach’s α value
for the PSQI is 0.83 [73].
Key RA outcomes Fatigue will be assessed with the
Bristol Rheumatoid Arthritis Fatigue Multidimensional
Questionnaire (BRAF-MDQ) for the previous 7 days
[74]. The BRAF-MDQ consists of 20 items with the op-
portunity to define five domains: total fatigue, physical
fatigue, living with fatigue, cognitive fatigue and emo-
tional fatigue. The total score ranges from 0 to 70, with
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Table 1 Cognitive behavioural therapy for insomnia: intervention overview
Session 1 Introduction Presentation
Goals
Expectations
Sleep education Normal sleep and its determinants
Sleep needs
Consequences of insomnia
Nature of insomnia
Evaluation of participant sleep
Sleep hygiene
Sleep restriction Introduce sleep diary
Session 2 Follow-up Since last session
Sleep education Sleep hygiene
Stimuli control Rationale; conditioned arousal
Instructions
Sleep restriction Rationale; sleep drive and sleep consolidation
Sleep efficiency and sleep window for week 2
Relaxation Bed time wind-down
Session 3 Follow-up Since last session
Stimuli control Experiences and challenges
Sleep restriction Experiences and challenges
Sleep efficiency and sleep window for week 3
Cognitive therapy Cognitions affecting sleep
Cognitive techniques to treat insomnia
Session 4 Follow-up Since last session
Sleep restriction Experiences and challenges
Sleep efficiency and sleep window for week 4
Cognitive therapy Experiences and challenges
Cognitive techniques to treat insomnia
Worry-time
Relaxation Rationale, break the tension and return to a relaxed state
Body scan meditation
Session 5 Follow-up Since last session
Stimuli control Experiences and challenges
Sleep restriction Experiences and challenges
Sleep efficiency and sleep window for week 5
Cognitive therapy Experiences and challenges
Cognitive techniques to treat insomnia
Relaxation Experiences and challenges
Session 6 Follow-up Since last session
Sleep restriction Experiences and challenges
Sleep efficiency and sleep window for week 6
Closure Plan for further work
Relapse prevention
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a higher score indicating more severity. The Cronbach’s
α value for BRAF-MDQ is >0.93 [75].
The impact of RA on daily life will be assessed with
the Rheumatoid Arthritis Impact of Disease (RAID)
questionnaire [76, 77]. RAID consists of seven items,
each of which is rated using a numerical rating scale of
0–10 with higher scores indicating more severity,
covering pain, physical function, fatigue, sleep, physical
well-being, mental well-being and coping for the previ-
ous 7 days. The Cronbach’s α value for RAID is >0.93
[75].
Depressive symptoms will be assessed with the
Hospital Anxiety and Depression Scale-Depression
(HADS-D) [78]. HADS-D measures depressive symp-
toms in the previous 7 days. Seven items are rated on a
four-point scale and scored from 0 to 3, with total scores
ranging from 0 to 21. Scores between 0 and 7 represent
‘no case’, 8 to 10 indicate ‘possible case’, 11–15 ‘moder-
ate case’ and ‘15–21’ suggest a ‘probable severe case of
depression’ [79]. The Cronbach’s α value for HADS-D is
0.82 [80].
Other secondary outcomes
We will examine other secondary outcomes after
treatment at week 7 and at follow-up at week 26 if CBT-
i has a significant positive effect on the primary outcome
of SE after treatment at week 7.
Other sleep outcomes SE, SOL, WASO and TST will
also be assessed with actigraphy to measure sleep
objectively for 7 continuous nights. Actigraph is an
objective measurement to assess sleep/wake behaviour
for several continuous nights and days [81, 82]. It allows
the participant to be mobile and to continue their
normal routines while data are recorded in a natural
sleep environment. In Sleep-RA, the actigraph is worn
on the non-dominant wrist for 7 continuous nights and
days. To validate or adjust the data from the actigraph,
the participants write down their bed times and rise
times and the use of the actigraph.
SE, SOL WASO and TST will be further assessed
subjectively with the PSQI [72, 73].
Other RA outcomes Fatigue severity, coping and effect
over the previous 7 days will be assessed with the Bristol
Rheumatoid Arthritis Fatigue Numerical Rating Scale
(BRAF-NRS) on a scale of 0–10, with higher scores
indicating greater severity. BRAF-NRS has shown good
criterion and construct validity [83].
RA-related pain will be assessed with a self-reported
visual analogue scale (VAS) for pain on a scale of 0–100,
with a higher score indicating greater severity [84].
Functional status will be assessed with the
Multidimensional Health Assessment Questionnaire
(MD-HAQ) [85]. The MD-HAQ measures self-reported
functional status over the previous 7 days on 10 items
covering dressing, rising, eating, walking, hygiene, reach,
grip and everyday activities. The mean of the MD-HAQ
score is calculated with a possible range of 0.0–3.0, with
a higher score indicating lower functional status. The
MD-HAQ is validated for patients with RA and has a
Cronbach’s α value of 0.65 for the psychological dimen-
sion and 0.88 for the physical dimension [86].
HRQoL will be assessed with the Short Form-36
health survey (SF-36) [87, 88]. This is a generic instru-
ment consisting of 36 multiple-choice questions
Fig. 2 Statistical method for key secondary outcomes
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contributing to the sum scores of physical and mental
health. The two scores of 0–100 are the weighted sums
of the items in their section, with a higher score indicat-
ing less disability. The SF-36 is validated and translated
to Danish. The Cronbach’s α value for SF-36 is >0.85
[89].
Disease activity will be assessed with DAS28-CRP.
DAS28-CRP is a composite index developed to make an
objective and reproducible assessment of RA disease ac-
tivity and has been validated for use in clinical trials [90,
91]. A DAS28-CRP <2.6 implies remission, ≥2.6 and ≤3.2
implies low disease activity, >3.2 and ≤5.1 implies mod-
erate disease activity, and >5.1 implies high disease
activity.
Tender and swollen joints will be assessed by a
physical examination of 28 joints, conducted by project
nurses [92].
CRP will be assessed from serum samples. A higher
CRP value indicates more inflammation [91, 93].
The patient global assessment of disease activity is a
self-reported assessment of the patient’s overall assess-
ment of how the arthritis is doing with the question:
“Considering all the ways your arthritis affects you, rate
how well you are doing on the following scale?” [94].
The patient reports “VAS global patient” from 0 to 100,
with a higher score indicating more disease activity [95].
The physician global assessment is a well-validated as-
sessment of the patient’s current disease activity [94].
The project nurses will report “VAS global physician”
from 0 to 100, with a higher score indicating more dis-
ease activity [95].
Additional information
Additional information includes sociodemographic
characteristics (education, employment, civil status,
children living at home), lifestyle (smoking, alcohol,
drugs, caffeine, physical activity), RA-related information
(duration of RA, rheumatoid factor of the immuno-
globulin M class, anti-citrullinated protein antibody,
CRP), sleep-related information (duration of insomnia,
sleep stages, number of awakenings, apnoea-hypopnoea
index, leg movements), comorbidity (diabetes, hyperten-
sion, heart attack, other heart disease, stroke, chronic
obstructive pulmonary disease, cancer, osteoarthritis,
osteoporosis, asthma, depression) and current medicine
(antirheumatic drugs, glucocorticoids, antidepressant
drugs, hypnotic drugs).
Participant timeline {13}
The trial period for each participant is approximately 6
months, and includes 6 weeks of CBT-i for participants
in the intervention group and 20 weeks of subsequent
outcome assessments for both groups. All participants
will complete the same outcome assessments at baseline,
after treatment (week 7) and at follow-up (week 26), as
presented in Fig. 1 and Table 2.
Sample size {14}
With a total sample size of 60 patients with RA (30
allocated to CBT-i as treatment and 30 allocated to
usual care), we will have more than 85% power to detect
a group difference in the primary outcome of average SE
assessed by PSG after treatment at week 7 and subse-
quently with reasonable power in the key secondary out-
come assessed at follow-up at week 26.
For a two-sample pooled t test of a normal mean dif-
ference with a two-sided significance level of 0.05 (P <
0.05), assuming a common standard deviation of 7.5% in
SE, a total sample size of 60 with allocation ratio of 1:1
has a power of 86.1% to detect a mean difference of 6
percentage points in SE.
The Sleep-RA trial is sufficiently powered to detect the
anticipated difference with a total sample size of 52 par-
ticipants. Assuming a balanced attrition rate (no more
than four withdrawals per group) we will obtain enough
statistical power (80.7%, i.e. >80%) to detect a mean dif-
ference of 6 percentage points in SE.
With a total sample size of 60 patients and assuming a
balanced design (1:1), exploratory analyses of any of the
secondary outcomes collected at week 26 will have
enough statistical power (>80%) to detect a standardised
mean difference of 0.80 (i.e. a Cohen’s effect size
corresponding to a large clinical effect).
Recruitment {15}
All patients at routine rheumatologic outpatient visits in
Denmark enter self-reported data on a touch screen
linked to the National Clinical Database for Rheumatol-
ogy (DANBIO) [96]. Potential participants for Sleep-RA
will be identified when they answer the question: “At
this moment, are you able to get a good night’s sleep?”
Patients who answer either “With much difficulty” or
“Unable to” will be presented with a pop-up message on
the screen containing brief information that a research
project on sleep is underway (and currently recruiting
participants). Patients who want further information can
type “yes” on the screen. KML will telephone each pa-
tient and will offer to send written information and sub-
sequent oral information. While giving the oral
information, it will be determined whether the patient
fulfils the criteria and can enter the trial.
Patients who are not eligible or do not wish to
participate in the trial will be registered in one of the
following three categories: 1) did not meet the
inclusion criteria; 2) declined to participate; or 3)
other reasons (Fig. 1).
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Assignment of interventions: allocation
Sequence generation {16a}
Randomisation will be conducted after baseline
assessment by computer-generated random numbers
with blocks of ten participants.
During randomisation, participants will be stratified by
disease activity to equalize the risk of change in
treatment with antirheumatic drugs during the trial
period and the effect this might have on sleep.
Stratification will be set to disease activity according to
Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) trial schedule
*Primary outcome; †key secondary outcomes; Δother secondary outcomes
BRAF-MDQ Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, BRAF-NRS Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scale, CBT-i
cognitive behavioural therapy for insomnia, CRP C-reactive protein, DAS28 Disease Activity Score-28, HADS-D Hospital Anxiety and Depression Scale-Depression,
HRQoL health-related quality of life, ISI Insomnia Severity Index, MDHAQ Multidimensional Health Assessment Questionnaire, PSG polysomnography, PSQI
Pittsburgh Sleep Quality Index, RA rheumatoid arthritis, RAID Rheumatoid Arthritis Impact of Disease, SE sleep efficiency, SF-36 Short Form-36 health survey, SOL
sleep-onset latency, TST total sleep time, VAS visual analogue scale, WASO wake after sleep onset
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DAS28-CRP ≤3.2 (low disease activity) and >3.2 (moder-
ate disease activity) measured at baseline [97].
Concealment mechanism {16b}
Allocation concealment will be ensured as it will not be
possible to conduct the computer-generated randomisa-
tion until the baseline assessment is completed for each
participant.
Implementation {16c}
An external collaborator (Zitelab Aps, http://www.
zitelab.dk/) will generate the allocation sequence. This
collaborator is not involved in outcome assessments or
the CBT-i intervention. KML will enrol participants and,
immediately after randomisation, inform them to which
group they have been allocated.
Assignment of interventions: blinding
Who will be blinded {17a}
Outcome assessments are conducted by project nurses
specialising in rheumatology, medical laboratory
technologists or neurophysiology assistants, all of whom
will be blinded to participant allocation.
Application of PSG equipment and instructions on
how to use the actigraph and subsequent analysis of data
will be conducted by neurophysiology assistants at the
DCSM. Patient-reported outcome measures will be col-
lected via questionnaires on tablets handed out by a pro-
ject nurse. To assess the outcome of disease activity, a
project nurse will examine the joints of participants to
identify the number of swollen and tender joints related
to DAS28. Blood samples will be taken and analysed by
a medical laboratory technologist.
KML will conduct the CBT-i intervention and is there-
fore not blinded to participant allocation.
Procedure for unblinding if needed {17b}
The trial design is open-label with only the outcome as-
sessors being blinded so unblinding will not occur.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data will be collected from PSG, actigraphy, physical
examination, blood samples, a medical journal and
questionnaires as presented in Table 2 and as follows.
The data collected from PSG cover SE, SOL, WASO,
TST, sleep stages, number of awakenings, apnoea-
hypopnoea index and leg movements. The data collected
from actigraphy cover SE, SOL, WASO and TST for 7
continuous nights. From the medical journal we will col-
lect data on duration of RA, anti-rheumatic drugs and
glucocorticoids. Questionnaires will provide data on
patient-reported SE, SOL, WASO, TST, insomnia, sleep
quality, fatigue, impact of RA, depressive symptoms,
pain, functional status, HRQoL, patient global assess-
ment, physician global assessment, sociodemographic
information, lifestyle, RA-related information, comorbid-
ity, duration of insomnia, antidepressant drugs and hyp-
notic drugs. From the physical examination we will
obtain data on swollen joints and tender joints counts
(of 28 examined joints), and we will collect data on CRP
from serum samples.
Plans to promote participant retention and complete
follow-up {18b}
Dates for assessments will be planned by KML together
with each participant, and all participants will receive a
text reminder on their telephone or an email the day
before a scheduled assessment. If participants withdraw
consent for follow-up assessment of one outcome, they
will be given the option to continue with assessments
for other outcomes.
Data management {19}
All participants will receive an identification code and all
data will be de-identified.
A list of identifiable participant information associated
with each identification code will be stored electronically
separately from the research data for 5 years. Patient-
reported information will be completed electronically on
a tablet, which will be used only for participants in this
trial and is linked to the DANBIO Reuma electronic case
report form.
Confidentiality {27}
All information collected during the trial will be kept
confidential in accordance with Danish Data Protection
Agency rules. All data will be processed confidentially
according to the Act on Processing of Personal Data.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
There will be no biological specimens collected for
genetic or molecular analysis in this trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
All main analyses will be conducted based on the
intention-to-treat (ITT) population. We plan to conduct
both an analysis of the full analysis set (patients with
outcome data available at baseline) and a per-protocol
analysis so that any differences between them can be ex-
plicitly discussed and interpreted. The ITT principle
states the effect of a treatment policy (i.e. the planned
treatment regimen) rather than the actual treatment
given. The consequence of conducting ITT analyses is
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that participants allocated to a treatment group should
be followed up, assessed and analysed as members of
that group, irrespective of their compliance to the
planned course of treatment. Robustness is a concept
that refers to the sensitivity of the overall conclusions to
various limitations of the data, assumptions and analytic
approaches to data analysis. Robustness implies that the
treatment effect and primary conclusions of the trial are
not substantially affected when analyses are carried out
based on alternative assumptions or analytical
approaches.
We will control the α level across only the most
important hypotheses by use of a hierarchical testing
strategy to preserve a type 1 error rate of 5% for the
primary outcome of change in SE assessed after
treatment at week 7, followed by SE assessed at follow-
up after 26 weeks. All the patient-reported outcome
measures and other secondary outcome measures will,
by principle, only be clinically relevant after 26 weeks.
The sleep-related key secondary outcomes (SOL,
WASO, TST, insomnia and sleep quality) will only be
considered statistically significant with a P value <0.01
(0.05/5). The RA-related key secondary outcomes (fa-
tigue, impact of RA and depressive symptoms) will only
be considered statistically significant with a P value <
0.017 (0.05/3) as described in Fig. 2.
In the Sleep-RA trial with repeated measures, partici-
pants will be randomly assigned to treatment groups,
and outcome observations are made at two time points
on each patient. We anticipate that measures on the
same patient at different times are correlated and that
measures taken close together in time will be more
highly correlated than measures taken further apart in
time; observations on different patients will be assumed
to be independent.
Data will be analysed using the PROC MIXED
procedure of the statistical program SAS System, with
baseline level as a covariable, using a multilevel
repeated-measures random-effects model, with partici-
pants as the random effect factor and based on a re-
stricted maximum likelihood estimate. For the primary
outcome measure, the after-treatment value will be the
response variable, and the baseline values of treatment
group (two levels), stratum (i.e. two levels according to
the randomisation) and time (two levels) will be the co-
variates. Assessment of these baseline values (main ef-
fects) will be of interest, along with the interaction
between treatment group and time. This statistical
model holds all between-group comparisons at both as-
sessment points and allows for evaluation of the average
effect over the period from baseline to follow-up at 26
weeks.
The SAS statistical package (v.9.4; SAS institute Inc.,
Cary, NC, USA) and R 3.0.1 (http://www.R-project.org,
the R Foundation for Statistical Computing) will be used
for the statistical models.
Interim analyses {21b}
We plan to include 60 patients, and the trial period for
each participant is 26 weeks. This is a non-
pharmacological 6-week intervention with no expected
adverse or harmful events, and the trial is therefore not
subject to independent safety monitoring and periodical
review, e.g. interim analyses.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
We have no intention to conduct subgroup and adjusted
analyses.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
We will apply the analysis framework suggested by
White et al. for ITT analysis that depends on making
plausible assumptions about the missing data and
including all participants in sensitivity analyses [98]. We
will:
1. Attempt to follow-up all randomised participants,
even if they withdraw from allocated treatment.
2. Perform a main analysis of all observed data that
are valid under a plausible assumption about the
missing data (missing at random). Our primary
analysis population will be all participants with
available data statistically modelled using
repeated-measures linear mixed models (see
below). These models will be valid if data are
missing at random (any systematic difference be-
tween the missing values and the observed values
can be explained by differences in observed data).
3. Perform sensitivity analyses to explore the effect of
departures from the assumption made in the main
analysis (data as observed; valid assuming that data
are missing completely at random).
4. Account for all randomised participants, at least in
the sensitivity analyses. We will analyse all variables
with missing data (due to withdrawals) being
replaced by imputation of the baseline level, i.e.
interpreted as assuming that those who dropped
out returned to their baseline level [99]. These
models will potentially be valid even if data are
‘missing not at random’ (even after the observed
data are considered, systematic differences remain
between the missing values and the observed
values).
In addition, data will be analysed according to the
per-protocol population, where data from participants
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who participated in a minimum of four out of six ses-
sions of CBT-i are included. The participants from
the control group will be considered per-protocol in-
dividuals if data are available from all three assess-
ments (baseline, after treatment at week 7, and
follow-up at week 26).
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
The datasets analysed during this trial are available from
the corresponding author on reasonable request.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
This trial proceeds from COPECARE (Copenhagen
Center for Arthritis Research), a multidisciplinary centre
which is internationally renowned and provides day-to-
day support for the trial. COPECARE represents the
steering group in collaboration with the University Hos-
pitals Centre for Nursing and Care Research, Parker In-
stitute and DCSM.
The steering committee consists of health
professionals with solid research and management
competences. The committee represents knowledge at
a high level from different professions: nurses,
rheumatologists, psychologist, neurophysiologist and
statistician. This ensures scientific quality,
multidisciplinary width and possible implementation
in clinical practice depending on the results of the
trial. The managers of the rheumatology department
participate in the steering committee and ensure
clinical anchoring and implementation.
Once a year an external assessor from the University
of Copenhagen is invited to a meeting with the project
management group to discuss progress in the trial and
methods to improve quality and stringency.
The daily project manager (KML) is affiliated to
COPECARE. She identifies all potential participants
from the recruiting sites through DANBIO (as explained
in the “Recruitment” section). She provides oral
information and received written consent.
Composition of the data monitoring committee, its role and
reporting structure {21a}
The intervention in this trial is a non-pharmacological
intervention with low or no risk of adverse or harmful
events. Therefore, there is no data monitoring commit-
tee. The trial is registered on www.clinicaltrials.gov and
approved by the Regional Ethics Committee and the Da-
nish Data Protection Agency.
Adverse event reporting and harms {22}
Participants will be monitored throughout the period of
the intervention to detect any unintended events.
Should a PSG show signs of a sleep disorder requiring
further examination or treatment the participant will be
contacted by DCSM after the final assessment is
completed.
Frequency and plans for auditing trial conduct {23}
The project management group meet twice a year and
conduct an audit of the trial.
When a participant has completed self-reported ques-
tionnaires on the tablet used in this trial, the project
nurse ensures that data are complete and imported to
the electronic case report form. When objective sleep
measures of PSG and actigraphy are completed, all data
are assessed for completeness by a neurophysiology as-
sistant. If any data are missing or of low quality, the par-
ticipant is invited to a new assessment.
Plans for communicating important protocol amendments
to relevant parties (e.g. trial participants, ethical
committees) {25}
Important protocol amendments which may impact the
content or conduct of the trial will be decided in the
steering group. Important protocol amendments will be
sent for approval to the ethics committee, notified to the
participating sites and addressed in the written and oral
information. Furthermore, the protocol registered on
www.clinicaltrials.gov will be updated prior to
implementation.
Dissemination plans {31a}
We plan to publish two scientific papers in peer-
reviewed journals based on the trial and to disseminate
the results to patient organisations and the public
through printed and electronic media.
Discussion
The Sleep-RA trial is designed to investigate the efficacy
of CBT-i on sleep and prevalent symptoms of fatigue,
impact of RA, depressive symptoms, pain, functional sta-
tus and HRQoL in patients with RA. To our knowledge,
this is the first trial to investigate an evidence-based
non-pharmacological intervention that, first and fore-
most, targets sleep-related cognitions and behavioural
challenges related to sleep disturbances in this
population.
Patients with RA have increased risk of fatigue,
depressive symptoms, pain, reduced functional status
and work capability. The severity of these symptoms is
often linked to the disease activity, and patients with
symptoms report that they feel constantly reminded of
their chronic disease. The degree and duration of the
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above-mentioned symptoms is unpredictable because of
the fluctuating character of RA. Living with one or more
of these symptoms or the awareness that they can occur
unexpectedly at any time can challenge the patient’s
ability to manage the arthritis and their daily life. Ac-
cording to Spielman’s conceptual “3P model” of insom-
nia, insomnia is caused by precipitating events such as a
change in health [100, 101]. Therefore, it is possible that
there is an increased risk of initial insomnia around the
time of diagnosis or when patients have arthritis flares
and experience symptoms, while not knowing how long
they will last. The development of chronic insomnia is
complex, and is mainly—if not solely—mediated by per-
petuating mechanisms [30]. RA symptoms are unpre-
dictable, and because sleep disturbances are also
associated with many of the same symptoms as RA, e.g.
fatigue, depressive symptoms, pain and HRQoL, this
could trigger, maintain and extend perpetuating mecha-
nisms. In the persistent search for better sleep quality
and more sleep, patients can develop a hyper-focus on
their lack of sleep. This often increases the patient’s risk
of obsession with sleep, followed by cognitions and be-
haviour that work against falling asleep [30, 36].
A positive effect of CBT-i will document CBT-i to be
an applicable and pertinent treatment of insomnia in pa-
tients with RA, as recommended in international guide-
lines for non-pharmacological treatment of insomnia
[62]. In addition, if the trial also finds positive effects re-
garding the secondary outcomes, such as fatigue, depres-
sive symptoms, pain, disease activity and functional
status, CBT-i will not only be relevant as a non-
pharmacological treatment option for insomnia but will
also have the potential to contribute positively in the
management of symptoms related to RA and insomnia.
The primary outcome in Sleep-RA is SE which can be
measured in different ways, e.g. with PSG, actigraphy,
PSQI and a sleep diary. Although PSG is perceived as
the most valid measure for SE [69], we are aware that
PSG could inconvenience the participants in terms of
the application of electrodes. Nevertheless, we found it
necessary to ensure that a measuring method of high
quality was used to generate results and because Sleep-
RA is the first trial to examine CBT-i in patients with
RA.
CBT-i is most often carried out by psychologists or
other professionals with training in psychology in private
clinics. Consequently, CBT-i is generally not accessible
at hospitals, either as a part of the patient’s current
treatment for RA or in the management of their symp-
toms. It is highly relevant to investigate the effect of
nurse-led CBT-i in patients with RA since significant
positive effects of CBT-i delivered in a group format by
nurses have been shown in randomised controlled trials
in European general practice settings [52, 53].
For future clinical purposes, we expect positive results
from Sleep-RA to contribute to increased awareness of
insomnia in rheumatology clinical practice. CBT-i has
the potential to contribute significantly to the treatment
of insomnia and, consequently, CBT-i has the potential
to reduce the prevalence of chronic insomnia. Many
symptoms of RA and insomnia are identical and some of
them can be challenging to treat. CBT-i may also have
comprehensive positive effects on the wide range of
symptoms and thereby potentially contribute to in-
creased physical and mental health and well-being in pa-
tients with RA.
Trial status
This is protocol version 1, 16 January 2020.
Initial release was on 30 November 2018. Recruitment
started on 17 December 2018, with an anticipated
primary completion date of 30 October 2020.
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